The 3′ UTR variants in the GRP78 are not associated with overall survival in resectable hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Zhu, Xiao ^a,d   Wang, Fang ^b   Lin, Marie C M ^c   Tian, Linwei ^d   Fan, Wenguo ^e   Ng, Samuel S ^f   Liu, Minjuan ^a   Huang, Jianqing ^a   Xu, Zhenhua ^c   Li, Dongpei ^e   Kung, Hsiangfu ^b,d  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SUN YAT SEN UNIVERSITY   (China)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; THYMINE; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; GRP78 GENE; HAPLOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION GENETICS; FOLLOW UP; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL;

3' UNTRANSLATED REGIONS; ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 79952943508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017783     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Kew MC, (2002) Epidemiology of hepatocellular carcinoma. Toxicology 181-182: 35-38.
3. Yang JD, Roberts LR, (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448-458.
4. Wang M, Wey S, Zhang Y, Ye R, Lee AS, (2009) Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal 11: 2307-2316.
5. Ni M, Zhou H, Wey S, Baumeister P, Lee AS, (2009) Regulation of PERK signaling and leukemic cell survival by a novel cytosolic isoform of the UPR regulator GRP78/BiP. PLoS One 4: e6868.
6. Su R, Li Z, Li H, Song H, Bao C, et al. (2010) Grp78 promotes the invasion of hepatocellular carcinoma. BMC Cancer 10: 20.
7. Zhu X, Li DP, Fan WG, Lin MC, Wang JL, et al. (2010) Lack of association between the GRP78 polymorphisms in the promoter and 3′ UTR and susceptibility to chronic HBV infection in a Chinese Han population. BMC Med Genet 11: 83.
8. Zhu X, Chen MS, Tian LW, Li DP, Xu PL, et al. (2009) Single nucleotide polymorphism of rs430397 in the fifth intron of GRP78 gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: risk and prognosis. Int J Cancer 125: 1352-1357.
9. Zhu X, Wang J, Wang Q, Zhang Y, Chen L, et al. No association between the haplotypic block in the 3′ UTR of GRP78 and risk of hepatocellular carcinoma. Hepato-gastroenterology. In press.
10. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
11. Kim KA, Lee WJ, Lim HK, Park CM, Park CK, et al. (2003) Small hepatocellular carcinoma: ultrasonographic findings and histopathologic correlation. Clin Imaging 27: 340-345.
12. Bellavance EC, Lumpkins KM, Mentha G, Marques HP, Capussotti L, et al. (2008) Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg 12: 1699-1708.
13. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, et al. (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59: 953-962.
14. Yano M, Hamatani K, Eguchi H, Hirai Y, MacPhee DG, et al. (2007) Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes. Eur J Cancer 43: 1092-1100.
15. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, et al. (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama 299: 53-60.
16. Nogueira JA, Ono-Nita SK, Nita ME, de Souza MM, do Carmo EP, et al. (2009) 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC Cancer 9: 204.
17. Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, et al. (2010) Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 52: 2034-2043.
18. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, et al. (2010) Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 42: 755-758.
19. Vormfelde SV, Brockmoller J, (2007) On the value of haplotype-based genotype-phenotype analysis and on data transformation in pharmacogenetics and-genomics. Nat Rev Genet 8.
20. Woodcock J, Lesko LJ, (2009) Pharmacogenetics-tailoring treatment for the outliers. N Engl J Med 360: 811-813.
21. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, et al. (2009) Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 4: e7765.
22. Rose MD, Misra LM, Vogel JP, (1989) KAR2, a karyogamy gene, is the yeast homolog of the mammalian BiP/GRP78 gene. Cell 57: 1211-1221.
23. Gonzalez-Gronow M, Selim MA, Papalas J, Pizzo SV, (2009) GRP78: a multifunctional receptor on the cell surface. Antioxid Redox Signal 11: 2299-2306.
24. Dong D, Ni M, Li J, Xiong S, Ye W, et al. (2008) Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 68: 498-505.